Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380058 | 0.90 | CYP1A2 (0.52) | SMN1; SMN2CYP1A2PPARGMAPTCA2 | |
| SCHEMBL5379171 | 0.90 | CYP1A2 (0.52) | SMN1; SMN2CYP1A2PPARGMAPTCA2 | |
| SCHEMBL3905083 | 0.90 | CHRM1 (0.57) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5379484 | 0.89 | CYP1A2 (0.53) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5372496 | 0.89 | CYP1A2 (0.53) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5370056 | 0.88 | METAP1 (0.43) | SMN1; SMN2CYP1A2PPARGMAPTMMP2 | |
| SCHEMBL5383535 | 0.87 | CYP1A2 (0.52) | SMN1; SMN2CYP1A2PPARGMAPTCA2 | |
| SCHEMBL2553558 | 0.87 | CYP1A2 (0.52) | SMN1; SMN2CYP1A2PPARGMAPTCA2 | |
| SCHEMBL3151682 | 0.87 | PPARG (0.53) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL17224011 | 0.85 | CHRM1 (0.52) | SMN1; SMN2CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| US-8569058-B2 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070043114-A1 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-7176240-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1685832-A1 | NERVE REGENERATION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20050267167-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | disclosed |
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | disclosed |
| US-20050261371-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-11-24 | — | — | US | disclosed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | disclosed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | disclosed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | SMN1; SMN2 373/4885CHRM1 93/4885AKR1A1 771/4885 |
| US-20070043114-A1 | Nerve regeneration promoters | BDNF, NGF, GAP43 | SMN1; SMN2 43/4885CHRM1 2671/4885AKR1A1 2042/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | SMN1; SMN2 138/4885CHRM1 84/4885AKR1A1 976/4885 |
| US-20050267167-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | SMN1; SMN2 373/4885CHRM1 93/4885AKR1A1 771/4885 |
| US-20050261371-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | SMN1; SMN2 402/4885CHRM1 84/4885AKR1A1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.